Using a clinical pneumococcal strain for which MICs were 4, 2, and 32 mg/liter for penicillin, amoxicillin, and fosfomycin, respectively, we studied the efficacies of these antibiotics alone and their combinations in the treatment of prolonged (48-h) experimental fibrin clot infection in rabbits. Treatments were as follows: amoxicillin IV at 20 mg/kg of body weight in one dose (Amo20), 50 mg/kg in one dose (Amo50), or two doses 6 h apart (Amo20 ؋ 2 and Amo50 ؋ 2); fosfomycin IV at a fixed dose of 50 mg/kg in one dose (Fos50) or two divided doses 6 h apart (Fos50 ؋ 2); or the combinations of amoxicillin and fosfomycin with the same schedules. Maximum concentrations in clots were 2.03 ؎ 1.02 and 2.13 ؎ 0.33 mg/liter for Amo20 regimens, 3.7 ؎ 1.9 and 4 ؎ 1.3 mg/liter for Amo50 regimens, and 24 ؎ 7 and 40 ؎ 8 mg/liter for fosfomycin regimens, respectively. The mean half-lives of elimination from clots were between 2 and 3 h for amoxicillin regimens and between 5 and 7 h for fosfomycin. We observed the highest bacterial reductions (log 10 CFU/gram) for Amo50 in two divided doses with or without fosfomycin. A significantly higher bacterial reduction than that with each monotherapy was observed when Amo20 was combined with fosfomycin in either one dose or two doses 6 h apart (0.16 ؎ 0.8 and 1.64 ؎ 1.6 log 10 CFU/g for Amo20 in one and two doses, respectively, and 0.93 ؎ 0.81 and 0.61 ؎ 0.56 log 10 CFU/g for fosfomycin in one and two doses, respectively, versus 3.46 ؎ 1.26 and 3.16 ؎ 1.31 log 10 CFU/g for Amo20 plus fosfomycin in one and two doses, respectively [P < 0.001]). A time-dependent effect was observed with amoxicillin regimens. The time of regrowth was significantly delayed when amoxicillin was combined with fosfomycin. By using a multivariate analysis, we demonstrated that the most important parameter correlated to efficacy of the combination amoxicillin-fosfomycin was the length of the period during which the concentration of amoxicillin remained above the MIC. We demonstrated that the in vivo efficacy of the combination of amoxicillin and fosfomycin gave higher antibacterial effect than each monotherapy.
Infections caused by Streptococcus pneumoniae continue to represent a significant cause of mortality and morbidity in humans (1, 18, 26) . A dramatic increase in the incidence of pneumococcal strains with resistance to penicillin and a range of other antimicrobial agents has been observed over the past two decades (1, 18) , and subsequently poor responses to therapy and increased mortality resulting from pneumococcal infections have been seen. The optimal therapeutic approach towards such cases is not known, but expanded-spectrum cephalosporins such as cefotaxime or ceftriaxone are the most commonly recommended (18, 26) . However, failures have been reported for monotherapy with these compounds (7, 9, 13, 17, 24, 26, 29) , and resistance to these antibiotics increases (26) with, sometimes, partial restoration of susceptibility to penicillin (11, 12, 26) .
As an option, treatment with amoxicillin, which has MICs lower than those of penicillin G and ampicillin (2) , can be associated with clinical cure of moderately and fully resistant nonmeningeal infections such as pneumonia. However, meningitis due to such strains cannot be cured with certainty with amoxicillin alone (15) .
Fosfomycin is a unique bactericidal antibiotic which exhibits good in vitro activity against both penicillin-susceptible and penicillin-resistant pneumococcal strains (14, 28) . It is also able to penetrate most infected tissues (27) .
Several authors have reported an in vitro synergy between ␤-lactam antibiotics and fosfomycin against penicillin-resistant pneumococcal strains (3, 4, 8, 28) , and therefore the following study was undertaken to evaluate whether this documented synergy is also apparent in vivo.
By using a prolonged (48-h) fibrin clot model in rabbits, we have tested the intrinsic therapeutic efficacies of amoxicillin and fosfomycin alone and in combination, and we purposely chose to investigate low antibiotic concentrations.
MATERIALS AND METHODS
Bacterial strain and susceptibility studies. The tested pneumococcal strain (no. 16089 [kindly provided by P. Geslin, Centre de Référence des Pneumocoques) was obtained from cerebrospinal fluid culture of a patient with meningitis. MICs of the study drugs were determined by the standard tube dilution technique, in which an inoculum of 5 ϫ 10 5 CFU and Mueller-Hinton broth supplemented with 5% horse blood, 0.25 ml of MgCl 2 , and 0.5 ml CaCl 2 were used. The MIC was defined as the lowest concentration of the drug that was required to inhibit visible growth. Since we used the fibrin clot model in rabbits, we checked for susceptibility of this pneumococcal strain in fibrin. The same dilution technique was used, but the broth was a 2.5% solution of sterile bovine fibrinogen in brain heart broth. As previously shown (10), MICs were the same with both methods and were 4, 2, and 32 mg/liter for penicillin, amoxicillin, and fosfomycin, respectively. Additionally, these results were confirmed by E test for penicillin and amoxicillin.
Experimental model. Infected fibrin clots were prepared as follows. A 2-ml sterile solution of 2.5% human fibrinogen was distributed into test tubes (13 by 100 mm) and infected with 100 l of a 5-h culture of the strain (inoculum, 10 5 to 10 6 CFU/ml). Human thrombin (Laboratoire Organon, Fresnes, France) was added to each tube, and then the tubes were incubated at 37ЊC for 1 h. The resulting clots were then gently removed and immediately inserted subcutaneously into rabbits.
We used a modified technique of the subcutaneous fibrin clot model in rabbits (6) in order to obtain a prolonged observation period of over 48 h. New Zealand White male rabbits (2 to 3 kg) were anesthetized with ketamine and xylazine. Then, (i) silastic central venous catheters were surgically placed by using a sterile operative technique to provide for continued nontraumatic venous access, and (ii) one flank was shaved and swabbed with iodine and alcohol, and then the skin was anesthetized with 2% lidocaine before a 4-cm incision was made. The day of the experiment, eight infected clots were placed in the subcutaneous pocket. Autoclips were applied to close the incision. Antibiotic regimens. Antibiotics were injected into rabbits immediately after clots were inserted. Each antibiotic was infused as a 30-s bolus. Rabbits were randomized to receive no drug (control), amoxicillin at 20 mg/kg of body weight at h 0 (Amo20), amoxicillin at 20 mg/kg at h 0 and 6 (Amo20 ϫ 2), amoxicillin at 50 mg/kg at h 0 (Amo50), amoxicillin at 50 mg/kg at h 0 and 6 (Amo50 ϫ 2), fosfomycin 50 at mg/kg at h 0 (Fos50), fosfomycin at 50 mg/kg at h 0 and 6 (Fos50 ϫ 2), amoxicillin at 20 mg/kg and fosfomycin 50 at mg/kg at h 0 (Amo20 ϩ Fos), amoxicillin at 20 mg/kg and fosfomycin at 50 mg/kg at both h 0 and h 6 [(Amo20 ϩ Fos) ϫ 2], amoxicillin at 50 mg/kg and fosfomycin at 50 mg/kg at h 0 (Amo50 ϩ Fos), amoxicillin 50 at mg/kg and fosfomycin at 50 mg/kg at both h 0 and h 6 [(Amo50 ϩ Fos) ϫ 2].
Determination of drug concentration and pharmacokinetics. Each clot was weighed and homogenized in a 2.5% solution of trypsin (Laboratoire Eurobio, Les Ulys, France), the volume of which was equal in weight to the clot. Trypsin had no effect on antibiotic activity and did not influence the bacterial count. Dissolved clots and serum samples were stored at Ϫ20ЊC for a few days before antibiotic assays.
Concentrations of amoxicillin were measured by an agar well diffusion microbioassay with a Staphylococcus capitis strain, highly resistant to fosfomycin. The detection limit was 0.08 mg/liter, the intra-assay variability was Ͻ3.5% in the range of observed concentrations (from 0.1 to 5 mg/liter), and the interassay variability was Ͻ5%. The presence of fosfomycin did not modify this assay. Concentrations of fosfomycin were measured by an agar well diffusion microbioassay with Serratia marcescens. The detection limit was 0.625 mg/liter, the intra-assay variability was Ͻ5% in the range of observed concentrations (from 1 to 4 mg/liter), and the interassay variability was Ͻ5%. When fosfomycin was of combined with amoxicillin, the ␤-lactam was hydrolyzed by the addition of cephalosporinase (600 U/ml) extracted from Serratia liquefaciens SL132. This procedure did not change the performance of the bioassay of fosfomycin. Standards of serum samples were diluted in 100% normal rabbit serum, whereas standards of fibrin clot samples were diluted in trypsinized fibrin clots.
Serum samples were obtained at the following times: 0 h 5 min, 1 h, 3 h, 6 h, 6 h 5 min, 7 h, 12 h, 24 h, 36 h, and 48 h. Fibrin clot samples were obtained at 0, 1, 3, 6, 7, 12, 24, 36, and 48 h. The area under the concentration-time curve (AUC) was obtained by the method of successive trapezoidal approximation. The half-lives of elimination of the antibiotics in serum and clots were calculated by the least-squares method. Maximal concentration was defined as the serum drug concentration at the 5th min after the end of the infusion; in clots, the maximum concentration was the highest observed. The length of the period during which the concentration of the drug remained above the MIC in fibrin clots (T Ͼ MIC) was calculated from each individual concentration-time curve.
In vivo efficacy. The efficacies of the various regimens were evaluated by the analysis of the bacterial contents of infected clots during each time interval using appropriate dilutions of trypsinized clots which were inoculated on blood agar and incubated at 37ЊC for 24 h (log CFU per gram of clot). The method was sensitive enough to detect Ն10 CFU/g. Time of regrowth was defined for each individual experiment as the time when the rate of bacterial growth became positive; the mean (Ϯ standard deviation) was then calculated for the antibiotic regimen. Also, the reduction of bacterial content in fibrin clots between time zero and time of regrowth (log 10 CFU per gram) was calculated for each individual experiment; this parameter defined the best bacterial effect for each individual experiment. By following the bacterial curve after this point, the rate of regrowth was calculated and expressed as log CFU per gram per hour.
Statistical analysis. The required number of experiments was determined with type I error of 5% and type II error of 20% for a two-sided test and a difference 
a The data are means Ϯ standard deviations. C max , maximum concentration of the drug in serum; T max , time to C max . Pairs of data marked with the following symbols are significantly different: *, P Ͻ 0.001; †, P ϭ 0.008; ‡, P ϭ 0.006; §, P Ͻ 0.001.
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SYNERGY OF AMOXICILLIN AND FOSFOMYCINof 1 log CFU. Therefore, results were expressed as means (Ϯ standard deviations) of at least five experiments for each antibiotic regimen. Statistics were performed by one-way analysis of variance, and the following tests were used for specific comparisons: the protected least-significant-difference test of Fisher was used to test the difference between the results of each couple of regimens, the contrast method was used to test the difference between specific groups of regimens (e.g., with or without fosfomycin), and the least significant range using the Newman-Keuls' test (with ␣ ϭ 0.05) was used to compare all treatments together. Univariate coefficient ratio estimates were computed with exact methods. A forward stepwise multivariate linear regression was used in an attempt to correlate efficacy and pharmacodynamic criteria. In order to standardize the comparison of all the regimens, the best bactericidal effect in each individual experiment (reduction in log 10 CFU/gram) at the time of regrowth was considered and the mean was calculated for each regimen. Significance was inferred if P was less than 0.05.
RESULTS

Pharmacokinetics. (i) Serum.
Pharmacokinetic data for each drug were obtained in serum studies with at least five animals ( Table 1 ). The highest mean concentrations in serum were observed 5 min after the administration of the bolus of amoxicillin and fosfomycin; no clear difference was observed after the second injection. The half-lives in serum were approximately 0.4 and 1.1 h for amoxicillin and fosfomycin, respectively. Consequently, the AUCs increased with the dose and the number of injections. No interactions between amoxicillin and fosfomycin were observed.
(ii) Fibrin clots. Pharmacokinetic data for fibrin clots are given in Table 1 and Fig. 1 . Mean maximal concentrations of amoxicillin were 2 and 4 mg/liter for the Amo20 and Amo50 regimens, respectively; of note, no clear increase in concentration was seen after the second injection (Fig. 1A) . For fosfomycin, the maximal concentrations were obtained 1 h after the first injection and a significant increase was observed after the second injection (24 Ϯ 7 versus 40 Ϯ 8 mg/liter, respectively). The respective half-life of amoxicillin was significantly shorter than that of fosfomycin (2.4 versus 6.1 h [means], respectively); no differences were observed between the amoxicillin regimens or between the fosfomycin regimens. Consequently, the AUCs significantly increased with the dose and the number of injections of amoxicillin and fosfomycin (Table 1) . No pharmacokinetic interactions between amoxicillin and fosfomycin were observed.
The T Ͼ MIC for this strain significantly increased with increases in both the dose of amoxicillin and the number of injections (Table 2) . These values were very small for the Amo20 regimens (0.8 and 1.2 h) compared with those for the Amo50 regimens (2.9 and 8.1 h). With this strain exhibiting a relatively high MIC of fosfomycin, the T Ͼ MIC values were also relatively small (0.5 and 4.3 h for Fos50 and Fos50 ϫ 2, respectively).
Bacteriologic effect. (i) Monotherapies. In the particular experimental conditions used in this study (i.e., relatively low dose) and following a single injection of amoxicillin, the reduction of the bacterial content was almost nil for Amo20 (0.16 log CFU/g) but significant when a second dose was added (1.6 log CFU/g) ( Table 2 and Fig. 2A) . At a higher dose of amoxicillin (50 mg/kg), the bacterial reduction was higher, and it was also higher for the two injection regimens (4.5 versus 3 log CFU/g for Amo50 ϫ 2 and Amo50, respectively). Although precocious regrowth was seen with single-dose regimens, similar results were seen at 24 h ( Table 2) .
The bacterial reduction observed with fosfomycin in one or two doses was modest (0.93 and 0.61 log CFU/g, respectively) ( Table 2 and Fig. 2B ).
The time of bacterial regrowth ( Table 2 and Fig. 2 ) was very rapidly reached at 1.5 h for Amo20 but was delayed at 12 h for Amo20 ϫ 2. Similarly, bacterial regrowth occurred at 6 h for Amo50 and at 43 h for Amo50 ϫ 2. For fosfomycin, this time was reached at 1.25 and 4.2 h (means) for Fos50 and Fos50 ϫ 2, respectively.
The rates of regrowth (Table 2 and Fig. 2) were the lowest for the most active regimens and vice versa. Of particular note, the two-injection regimens with amoxicillin or fosfomycin led to lower rates of bacterial regrowth than single-injection regimens.
(ii) Combination therapies. At each dose the combination amoxicillin-fosfomycin resulted in a significantly higher bacterial reduction than monotherapies (Table 2 and Fig. 2) . However, no difference was seen between Amo50 ϫ 2 and (Amo50 ϩ Fos) ϫ 2, since the bacterial efficacy of the former regimen was maximal. For example, the addition of one dose 
a The data are means Ϯ standard deviations. Rankings were based on the Newman Keuls' test, and, if significance was reached, the contrast method was used (level of significance, P Ͻ 0.05).
b Amo20 Յ Amo20 ϫ 2 Ͻ Amo50 Ͻ Amo50 ϫ 2; Fos50 Ͻ Fos50 ϫ 2. c Amo50 ϫ 2 Ϸ (Amo50 ϩ Fos) ϫ 2 Ͼ all other regimens; Amo20 Ͻ Amo20 ϫ 2; Amo50 Ͻ Amo50 ϫ 2; amoxicillin monotherapies Ͻ combinations with fosfomycin. d Amo20 Ͼ all other amoxicillin regimens. e Amo20 Ϸ Fos50 ϫ 2 Ϸ Fos50 Ͻ Amo20 ϫ 2 Ͻ Amo50 Ͻ all other regimens; amoxicillin monotherapies Ͻ combinations with fosfomycin. f Amo20 Ϸ Fos50 Ͼ Amo20 ϩ Fos Ϸ Fos50 ϫ 2 Ϸ Amo50 Ͼ (Amo20 ϩ Fos) ϫ 2 Ϸ Amo50 ϩ Fos Ͼ all other regimens; single-dose monotherapies Ͼ two-injection monotherapies; single-dose amoxicillin monotherapies Ͻ single-dose combinations.
of fosfomycin to one low dose of amoxicillin (Amo20) led to an increase in bacterial reduction of 3 log CFU/g. The time of regrowth was delayed when fosfomycin was added to amoxicillin (Table 2 and Fig. 2 ). It was especially true for the one-dose regimens (1.5 Ϯ 2 and 6 Ϯ 2.7 h for Amo20 and Amo50, respectively, versus 6.75 Ϯ 3.4 and 10 Ϯ 7 h for the corresponding combinations). However, no difference was seen between Amo50 ϫ 2 and (Amo50 ϩ Fos) ϫ 2, since the bacterial efficacy was maximal.
The rates of bacterial regrowth were also lower when fosfomycin was added to Amo20 and Amo50 regimens but not for the two amoxicillin injection regimens (Table 2 and Fig. 2) .
Correlation of pharmacokinetic parameters with therapeutic efficacy. For this analysis, in an attempt to compare all the regimens together, the reduction in log 10 CFU per gram at the time of regrowth was used ( Table 2 ). The maximal concentrations, the time above MIC, and log AUC were entered into this analysis as independent factors.
For amoxicillin, the factors significantly correlated to efficacy were maximum concentration of the drug in serum C max (P ϭ 0.0023; r 2 ϭ 0.278), T Ͼ MIC (P ϭ 0.0001; r 2 ϭ 0.446), and log AUC (P ϭ 0.0005; r 2 ϭ 0.346). In a multivariate analysis, T Ͼ MIC was the only parameter significantly correlated to efficacy (P Ͻ 0.0001; r 2 ϭ 0.35). For fosfomycin, whose antibacterial efficacy was rather modest, no significant correlation was found.
Also, the only correlation found for the combination regimens was that for the T Ͼ MIC of amoxicillin (P ϭ 0.0228; r 2 ϭ 0.184).
DISCUSSION
Under the experimental conditions used in this study, the level of antibiotic susceptibility of the strain was not altered in the fibrin clots and was the same as that obtained in vitro. Considering that no significant host response exists within the clots, our animal model allowed us to investigate the intrinsic pharmacodynamic parameters of the tested therapeutic regimens on this specific pneumococcal strain. In addition, we chose relatively low doses of amoxicillin and fosfomycin in order to maximize the probability of detecting an eventually higher antibacterial effect when the combinations were tested. Indeed, the maximal concentrations of amoxicillin and fosfomycin obtained in fibrin clots were those observed in human tissues such as meningeal space or middle ear fluid (20, 21, 23, 27) .
Two main findings can be drawn from this study. First, the augmentation of the amoxicillin dosage was clearly associated with greater antibacterial effect against this highly penicillinresistant pneumococcal strain. This finding is concordant with previous findings for experimental tissue infections using such a strain and amoxicillin (5) or penicillin (22) and also with several clinical observations of moderately resistant strain infections (16, 30) . These observations clearly favor increasing the dosage of amoxicillin in the treatment of such infections (25) .
The most important pharmacokinetic parameter determining the effect of amoxicillin in vivo was the T Ͼ MIC for this strain. This finding is in accordance with other data (19, 22) . Thus, dosing regimens which secure amoxicillin concentrations above the MIC, rather than a high peak of concentration, could be suggested for the treatment of infections caused by penicillin-resistant pneumococci.
The second main finding of this study was that amoxicillin combined with fosfomycin led to either a greater bacterial reduction, a more prolonged antibacterial effect, or a regrowth rate lower than those observed with monotherapies. All the combinations led to greater bacterial reductions than did either monotherapy.
Considering that (i) the most important parameter which correlated with efficacies of the amoxicillin-fosfomycin regimens was the T Ͼ MIC of amoxicillin and (ii) the concentrations of both amoxicillin and fosfomycin were rather low and easily achievable in humans, it could be suggested that this combination could overcome the resistance of such strains of pneumococci.
Conclusion. Using an in vivo model of infection caused by a highly penicillin-resistant pneumococcal strain, we demonstrated that combinations of amoxicillin and fosfomycin had very large antibacterial effects. As previously observed with other ␤-lactam antibiotics and another pneumococcal strain (10) , this kind of combination increased bacterial reduction, delayed the time of regrowth, or decreased the rate of regrowth. Consequently, these results favor the use of these combinations for the treatment of resistant pneumococcal infection.
